上市生物製藥公司 Acurx Pharmaceuticals 計劃購買價值 100 萬美元的比特幣

Acurx Pharmaceuticals 是一家生物製藥公司，開發用於治療難以治療的細菌感染的新型抗生素，該公司計劃購買高達 100 萬美元的比特幣

Biopharmaceutical company Acurx Pharmaceuticals (NASDAQ:ACXP) is set to purchase up to $1 million in Bitcoin (CRYPTO: BTC) to hold the apex cryptocurrency as a “treasury reserve asset” on its balance sheet.

生物製藥公司 Acurx Pharmaceuticals（納斯達克股票代碼：ACXP）計劃購買最多 100 萬美元的比特幣（CRYPTO：BTC），以將頂級加密貨幣作為其資產負債表上的「國庫儲備資產」。

The board-approved strategy will see the New York-headquartered company leverage Bitcoin’s characteristics, which will provide a “functional store of value,” the company said in a press release on Saturday.

該公司在周六的新聞稿中表示，董事會批准的策略將使這家總部位於紐約的公司利用比特幣的特性，這將提供「功能性的價值儲存」。

“As demand for Bitcoin grows, and so does its acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset for cash not needed over the next 12 to 18 months,” said David P. Luci, Acurx Pharmaceuticals president and chief executive.

David P. Luci 表示：「隨著對比特幣的需求不斷增長，以及它作為主要資產類別的接受度不斷提高，我們相信比特幣將成為未來12 至18 個月內不需要的現金的強大國庫儲備資產。

“With the recent approval of Bitcoin ETFs and the growing support from government agencies and institutional investors, it is a great addition to our treasury strategy.”

“隨著最近比特幣 ETF 的批准以及政府機構和機構投資者日益增長的支持，這是對我們財務策略的重要補充。”

The biopharmaceutical company’s move into Bitcoin comes as several companies are showing interest in the cryptocurrency. Earlier this year, Block Inc (NYSE:SQ) said it will allow users of its Cash App to send Bitcoin payments to friends and family members via email.

這家生物製藥公司進軍比特幣之際，多家公司對加密貨幣表現出了興趣。今年早些時候，Block Inc（NYSE：SQ）表示，將允許其 Cash App 用戶透過電子郵件向朋友和家人發送比特幣付款。

Also Read: 5 Things To Know Before The Market Opens Monday

另請閱讀：週一開市前需要了解的 5 件事

Acurx Pharmaceuticals, founded in 2017, is a late-stage biopharmaceutical company that develops novel antibiotics targeting difficult-to-treat bacterial infections, particularly Gram-positive pathogens.

Acurx Pharmaceuticals 成立於 2017 年，是一家後期生物製藥公司，開發針對難以治療的細菌感染（特別是革蘭氏陽性病原體）的新型抗生素。

The company is focused on advancing its lead product candidate, Ibezapolstat, through late-stage clinical development and regulatory approval.

該公司致力於透過後期臨床開發和監管批准來推進其主要候選產品 Ibezapolstat。

Acurx Pharmaceuticals began trading on Nasdaq in 2021. Following the latest news, Acurx shares rose 6.6%, trading at $1.78 in pre-market trading, according to data from Nasdaq.

Acurx Pharmaceuticals 於 2021 年開始在納斯達克交易。